Ondansetron Arrow

Ondansetron, the active ingredient in Ondansetron Arrow, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetron Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Arrow is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: helps control acute and delayed episodes in cancer patients. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms during radiotherapy. - Post‑operative nausea and vomiting: decreases incidence of nausea after surgical procedures. - Pregnancy‑related hyperemesis gravidarum: provides relief when other measures are insufficient. - Anticipatory nausea: lessens nausea that occurs before chemotherapy in patients with a history of severe CINV.

Side effects of ondansetron are generally mild but can vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Injection site pain (if administered parenterally).

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperreflexia, tremor when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Severe constipation or intestinal obstruction. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron Arrow, clinicians should consider several safety measures.

- Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk. - Electrolyte balance: correct hypokalaemia, hypomagnesemia, or hypocalcaemia before therapy. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Pregnancy: weigh benefits against potential risks; use only if clearly needed. - Breastfeeding: assess infant exposure risk before continuation. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Ondansetron may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amiodarone: additive risk of QT prolongation. - Certain anti‑arrhythmics (e.g., sotalol, quinidine): heightened arrhythmia risk. - Tricyclic antidepressants: may increase QT interval.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, fluconazole): may raise ondansetron plasma levels. - Macrolide antibiotics (erythromycin, clarithromycin): potential QT prolongation. - Atypical antipsychotics (ziprasidone, haloperidol): monitor cardiac rhythm. - Serotonergic agents (SSRIs, SNRIs, tramadol): watch for serotonin syndrome.